Behavioral and Psychological Symptoms of Dementia by J. Cerejeira et al.
REVIEW ARTICLE
published: 07 May 2012
doi: 10.3389/fneur.2012.00073
Behavioral and psychological symptoms of dementia
J. Cerejeira1*, L. Lagarto1 and E. B. Mukaetova-Ladinska2
1 Serviço de Psiquiatria, Centro Hospitalar Psiquiátrico de Coimbra, Coimbra, Portugal
2 Institute for Ageing and Health, Newcastle University, Newcastle uponTyne, UK
Edited by:
João Massano, Centro Hospitalar de
São João and Faculty of Medicine
University of Porto, Portugal
Reviewed by:
Federica Agosta, Vita-Salute San
Raffaele University, Italy
Luísa Alves, Centro Hospitalar de
Lisboa Ocidental, Portugal
*Correspondence:
J. Cerejeira, Serviço de Psiquiatria,
Centro Hospitalar Psiquiátrico de
Coimbra, Coimbra 3000-377, Portugal.
e-mail: jcerejeira@netcabo.pt
Behavioral and psychological symptoms of dementia (BPSD), also known as neuropsy-
chiatric symptoms, represent a heterogeneous group of non-cognitive symptoms and
behaviors occurring in subjects with dementia. BPSD constitute a major component of
the dementia syndrome irrespective of its subtype. They are as clinically relevant as cog-
nitive symptoms as they strongly correlate with the degree of functional and cognitive
impairment. BPSD include agitation, aberrant motor behavior, anxiety, elation, irritability,
depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes.
It is estimated that BPSD affect up to 90% of all dementia subjects over the course of their
illness, and is independently associated with poor outcomes, including distress among
patients and caregivers, long-term hospitalization, misuse of medication, and increased
health care costs. Although these symptoms can be present individually it is more common
that various psychopathological features co-occur simultaneously in the same patient.Thus,
categorization of BPSD in clusters taking into account their natural course, prognosis, and
treatment response may be useful in the clinical practice. The pathogenesis of BPSD has
not been clearly delineated but it is probably the result of a complex interplay of psycholog-
ical, social, and biological factors. Recent studies have emphasized the role of neurochem-
ical, neuropathological, and genetic factors underlying the clinical manifestations of BPSD.
A high degree of clinical expertise is crucial to appropriately recognize and manage the neu-
ropsychiatric symptoms in a patient with dementia. Combination of non-pharmacological
and careful use of pharmacological interventions is the recommended therapeutic for man-
aging BPSD. Given the modest efﬁcacy of current strategies, there is an urgent need to
identify novel pharmacological targets and develop new non-pharmacological approaches
to improve the adverse outcomes associated with BPSD.
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INTRODUCTION
During the natural course of dementia a heterogeneous group
of clinical phenomena is subjectively experienced by the patient
and/or observable by an examiner (e.g., caregiver, physician) con-
sisting in disturbed emotions, mood, perception, thought, motor
activity, and altered personality traits. These “neuropsychiatric
symptoms,” according to the terminology most used in the United
States, or “behavioral and psychological symptoms of demen-
tia” (BPSD), as designated by the International Psychogeriatrics
Association (Finkel et al., 1996), are very common and associated
with high levels of distress both in dementia sufferers and their
caregivers, as well as with adverse outcomes and increased use of
health care resources. Thus, in addition to cognitive deterioration,
BPSD are a relevant andmeaningful clinical target for intervention
(Katona et al., 2007).
BPSD: CONCEPTUAL OVERVIEW
BPSD IN THE CURRENT CLASSIFICATION SYSTEMS
Despite being almost universally present during the course of
dementia, BPSD have not been included in the deﬁning criteria
of dementia in the current classiﬁcation systems. The core fea-
tures of dementia according to DSM-IV-TR and ICD-10 consist
of gradual onset of multiple cognitive deﬁcits (involving memory
and at least one additional cognitive domain) not occurring exclu-
sively during delirium and representing a decline from a previous
level of functioning (American Psychiatric Association, 1994). In
DSM-IV-TR the presence or absence of a clinically signiﬁcant
behavioral disturbance can be coded, but no guidance is provided
about the diagnostic criteria of these symptoms. It is also possible
to code dementia (e.g., Alzheimer disease, AD) in axis III and spe-
ciﬁc mental disorders (e.g., mood or psychotic disorder) in axis
I with the advantage of better characterizing prominent clinical
features related to dementia (American Psychiatric Association,
1994).
PSYCHOPATHOLOGICAL FEATURES
Neuropsychiatric symptoms in subjects with dementia are het-
erogeneous and largely unpredictable, affecting the emotional
experience, thought content, perception, and motor function.
While some symptoms can be more often recognized in a spe-
ciﬁc pathological sub-type, the clinical presentation has a wide
variation within each sub-type and even within each dementia
individual. The ﬁrst step to better understand the psychiatricman-
ifestations of dementia is to appropriately recognize and describe
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the psychopathology and accurately distinguish between similar
symptoms (e.g., depression vs. apathy). This can be challenging
considering the overlap between symptoms and the lack of proper
deﬁnitions and consensus criteria for their diagnosis. Secondly, it is
useful to evaluate whether speciﬁc symptoms occur in association
and to group them in syndromes with common clinical evolution,
neurobiology, and management.
Disturbances in emotional experience
As the symptomsof depression are frequentlymaskedbydementia,
the patient rarely is able to express the typical pathological feelings
of sadness, unhappiness, and preoccupation with depressing top-
ics, hopeless (strongly associated with suicidal ideation) and loss
of self-esteem (Prado-Jean et al., 2010). Instead, the prominent
symptoms can be anhedonia (lost of interest in previous plea-
surable stimuli), expression of somatic concerns and anxiety, a
subjective unpleasant experience of fear manifested as apprehen-
sion, tension,panic,orworry associatedwith autonomic activation
and observable physical and motor manifestations of tension. In
the context of dementia, apathy has been deﬁned as a disorder
of motivation with additional loss or diminished goal-directed
behaviors, cognitive activities and emotions (Robert et al., 2009).
Apathy may be mistaken for depression because both symptoms
can manifest themselves as diminished interest, slowing and lack
of energy (Mulin et al., 2011). Although lack of motivation occurs
both in apathy and depression, apathy denotes a lack of motiva-
tion without dysphoria. Elated mood, ranging from hypomania
to severe mania, refers to a sustained and exaggerated feeling of
well-being, cheerfulness, euphoria that is out of proportion to
the circumstances often associated with a heightened emotional
tone or emotional reactivity. Both depression and elated mood
are commonly associated with irritability, a pervasive feeling of
unease in response to a sense of threat with enhanced readiness
to hostile attitudes or actions, which can be aggravated by hunger,
sleepiness, and pain. Affective (or mood) lability is characterized
by rapid emotional shifts, within seconds or minutes.
Delusions and abnormal thought content
Delusional ideas (false believes strongly held, enduring, and
irrefutable) can vary widely in respect to complexity, systemati-
zation, conviction, and the extent to which patients take action
in response to them. The delusions are typically less complex
and organized than those observed in non-demented psychotic
patients and the usual content of delusional thoughts involves
suspiciousness, abandonment, and misidentiﬁcation (Jeste et al.,
2006). Common examples include the conviction that: people are
coming into the home and hiding/stealing objects; the place in
which one is residing is not one’s home; conviction that spouse is
an impostor (Capgras delusion); accusation of a conspiracy to
abandon or institutionalize; conviction that spouse is unfaith-
ful; believes that other persons have acted maliciously; or with
discriminatory intent (Tariot et al., 1995). When associated with
severe depression, delusional thoughts can involve guilt,worthless,
reference, and persecution.
PERCEPTUAL DISTURBANCES
Perceptual disturbances in dementia can occur in every sensorial
modality. In some instances, it is somewhat difﬁcult to ascertain
whether the perceptual disturbance is an illusion or whether the
patient is having a perception in the absence of sensory stimuli
(hallucination). Visual hallucinations are particularly common in
subjects with dementia with Lewy bodies (DLB). They are recur-
rent, and typically consist of well formed images of animals or
persons that the patient describes in detail (McKeith et al., 2005).
DISTURBANCES IN MOTOR FUNCTION
Unlike the prior psychopathological domains, disturbances in
motor function can be directly observed and consist in reduced or
increased motor activity, not necessarily associated with speciﬁc
motor abnormalities. In motor retardation the patient presents
with slowed movements and speech, reduced body tone, and
decreased number of spontaneous body movements, whereas
motor hyperactivity is characterized by an increased energy level
with more frequent movements and/or rapid speech.
Agitation has been deﬁned as “inappropriate verbal, vocal, or
motor activity that is not judged by an outside observer to result
directly from the needs or confusion of the agitated individual”
(Cohen-Mansﬁeld et al., 2010). This term is used interchange-
ably with aberrant motor behavior and encompasses a range of
activities such as wandering away from home; repetitive, pur-
poseless behaviors; social inappropriate activities including those
associatedwith disinhibition (tendency to disregard social and cul-
tural norms and not restrain inner feelings, such as sexual drives).
According to Cohen-Mansﬁeld (1999) four distinct categories of
agitation are: (1) physically non-aggressive behavior; (2) verbally
non-aggressive behavior; (3) physically aggressive behavior; and
(4) verbally aggressive behavior.
CIRCADIAN RHYTHMS
Sleeppattern changesmayoccur as a consequence of normal aging,
but are particularly prevalent in individuals with dementia. These
include hypersomnia, insomnia, sleep-wake cycle reversal, frag-
mented sleep, and rapid eye movement sleep behavior disorder.
Patients with dementia often show daytime napping and night-
time awakenings associated with poor quality of sleep (Rongve
et al., 2010). Several factors, e.g., pain, need to urinate during the
night, medications (diuretics), as well as stimulants such as coffee
and bronchodilators, may contribute to this problem.
APPETITE AND EATING BEHAVIOR
Appetite changes can be quantitative (anorexia or hyperphagia)
or qualitative (preference for particular foods associated or not
to changes in taste). The preference for sweets is particularly fre-
quent in fronto-temporal dementia. Most dementia patients lose
weight which can be due to hypermetabolism and inﬂammatory
processes, in relation with hormonal disturbances.
BPSD ASSESSMENT
The assessment of neuropsychiatric symptoms requires a thorough
examination to collect speciﬁc and detailed information about
the clinical history, patient’s subjective experiences, and objective
behavior. Information from a reliable family member or caregiver
is essential to obtain adequate characterization of neuropsychiatric
disturbances from the patient’s own ecological context as many
abnormal symptoms cannot be elicited during the clinical inter-
view.Whendeterminingwhether the disturbances requiremedical
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attention it is useful to promote early interventions instead of a
crisis-based or reactionary approach.
INTERVIEW WITH THE PATIENT
Although subjects with dementia may be handicapped in their
communication and social skills, it is essential to have an individ-
ual assessment with them. Whenever possible, it is desirable that
patients are encouraged to express their own concerns in answer to
open questions before proceeding to a more systematic approach
to speciﬁc symptoms. Patient’s free descriptions are least prone to
be inﬂuenced by the interviewer and/or caregiver and can provide
crucial information about emotional states underlying behaviors.
CAREGIVER INTERVIEW
The interview with caregivers is an opportunity to characterize
the psychopathological features and to recognize which BPSD are
of greatest concern to them as these may not necessarily coincide
with the patient’s own complaints or with the clinician’s priorities.
Understanding the sources of these discrepancies is important
to determine the usefulness and limitations of the information
obtained from both patients and caregivers as caregiver’s emo-
tional state can inﬂuence assessment ratings (Logsdon et al., 1999;
Snow et al., 2005; Karlawish et al., 2008). In some parts of the
assessment, it is important to observe how caregivers interact with
the patient and how symptoms are manifested in such interac-
tions. Behavioral symptoms, particularly apathy, have a signiﬁcant
impact in the patient–caregiver relationship deterioration (deVugt
et al., 2003) and subjects with dementia are likely to be affected
by dysfunctional interactions with their caregivers (de Vugt et al.,
2004; Sink et al., 2006). Caregiver’s characteristics, such as younger
age, less education,depressive symptoms,andmorehours perweek
providing care assistance, appear to contribute to the presence
of or reported higher rates of BPSD (Sink et al., 2006). How-
ever, more research is needed to clarify how the patient–caregiver
interpersonal interactions contribute to the presence of certain
neuropsychiatric symptoms.
STANDARDIZED CLINICAL ASSESSMENT
Several validated instruments have been developed to quan-
tify BPSD based on data collected from clinical assessment of
dementia patients and caregivers’ interviews with some scales
assessing a wide range of neuropsychiatric symptoms and oth-
ers focusing on speciﬁc symptoms (e.g., aggression and agitation).
Self-administered questionnaires are also available for caregivers.
The ﬁrst behavior rating scale for AD was the BEHAVE-AD
(Reisberg et al., 1987), evaluating the presence and severity of 25
behavioral symptoms in 7 symptomatic categories (paranoid and
delusional ideation, hallucination, activity disturbances, aggres-
siveness, sleep disturbances, affective symptoms, and anxieties and
phobias), and providing a global rating of caregiver burden. Cur-
rently, one of the most extensively used instruments to assess
BPSD is the Neuropsychiatric Inventory (NPI) whose validity and
reliability has been well established in several languages (Cum-
mings, 1997). It consists of a semi-structured interview retrospec-
tively assessing 12 symptoms based on the caregiver information:
delusions, hallucinations, agitation, depression, anxiety, apathy,
irritability, euphoria,disinhibition,aberrantmotor behavior,night
time behavior disturbances, and eating behavior abnormalities.
Important factors to take into account when selecting an instru-
ment include the purpose of the assessment (e.g., comprehensive
vs. speciﬁc symptom evaluation) and the setting (e.g. busy clinical
practice vs. research).Whenpossible, it is advisable to obtain infor-
mation from different caregivers to cover behavior in different
settings, and thus providing an overall picture of patient’s func-
tioning. Disagreements among informants should be regarded as a
valuable cue to identify situational factors implicated in the genesis
of symptoms. It is unlikely that new rating scales will completely
solve the problems that are inherent in the assessment of BPSD.Yet,
future challenges lie in the improvement of the construction and
the use of the scales with an increasing need for more standardized
assessment of BPSD and for evaluation of their treatment.
CLINICAL RELEVANCE OF BPSD
PREVALENCE AND SEVERITY OF INDIVIDUAL SYMPTOMS
There is an overall agreement that BPSD are very common regard-
less of the type of dementia and are present in virtually all patients
during the course of their disease. Even in the early stages of
cognitive impairment, neuropsychiatric symptoms are frequent
with estimated rates of 35–85% in subjects with mild cognitive
impairment (MCI; Monastero et al., 2009).
The reported frequency of BPSD largely depends on the type
of sample and setting considered. In community-dwelling subjects
with dementia, neuropsychiatric symptoms are generally less fre-
quent (56–98%) and severe than in patients recruited in hospital
or long-term care facilities (91–96%). When looking at individual
symptoms in dementia patients, the most prevalent BPSD are apa-
thy, depression, irritability, agitation and anxiety, while the rarest
are euphoria, hallucinations, and disinhibition. The most clin-
ically signiﬁcant symptoms are depression, apathy, and anxiety.
Importantly, 50% of patients have at least four neuropsychiatric
symptoms simultaneously (Frisoni et al., 1999).
THE BURDEN OF BPSD
BPSD are a source of signiﬁcant distress and poor quality of life
(QoL) to both dementia patients and their caregivers (Ryu et al.,
2011). In AD patients, depressive symptoms are associated with
worse self-reported QoL scores (Karttunen et al., 2011) whereas
mood and psychotic symptoms predict changes in the QoL 2
years later (Tatsumi et al., 2009). Moreover, increased number of
BPSD correlates negatively with survival rates over a 3-year period
(Tun et al., 2007) whereas presence of psychosis in AD has been
found to be associated with increased mortality and acceleration
of cognitive decline (Emanuel et al., 2011; Russ et al., 2011).
BPSD also have a profound physical and psychological impact
on both formal and informal caregivers. A considerable part of
caregivers’ time and distress relate directly to the manifestation
of BPSD (Ballard et al., 2000a), which is a major reason for ear-
lier institutionalization of patients (Chan et al., 2003). Nursing
home placement determines a signiﬁcant increase in the overall
cost of dementia care in addition to other direct and indirect costs
associated with BPSD (Beeri et al., 2002; Herrmann et al., 2006).
Psychotic symptoms (e.g., delusions) and disruptive behaviors
(e.g., aggression, screaming) have been reported to be the most
burdensome to caregivers (Miyamoto et al., 2010; Rocca et al.,
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2010; Huang et al., 2011). In addition to BPSD, certain charac-
teristics of caregivers are known to determine the risk of burden
including overload, quality of the relationship with the patient,
adverse life events, gender, level of neuroticism, role captivity, and
levels of conﬁdence (Campbell et al., 2008).
In MCI subjects, comorbid neuropsychiatric symptoms
have been associated with worse cognitive performance, mild
extrapyramidal signs, and functional disability (Monastero et al.,
2009). Depressive symptoms in subjects with MCI have also been
linked to progression to dementia (Modrego and Ferrández, 2004;
Gabryelewicz et al., 2007) and increased brain atrophy over 2 years
(Lee et al., 2012) suggesting that they may represent an early sign
of a neurodegenerative disease.
SYMPTOMS INTERRELATION AND EVOLUTION
The unitary concept of BPSD encompassing the full range of emo-
tional, psychological, and behavioral abnormalities occurring in
dementia reﬂects the clinical heterogeneity and complexity of the
symptoms and the difﬁculty in characterizing more speciﬁc sub-
syndromes or proprieties clusters co-varying during the course
of the disease. Several studies have tried to identify neuropsychi-
atric sub-syndromes by grouping a number of individual symp-
toms which contingently co-occur during the course of dementia
(Table 1). Ultimately, the recognition of discrete clinical entities
is important to disclose underlying causal mechanisms and to
develop etiological-based therapeutic interventions, even if the
precise delineation of each syndrome remains elusive.
Although these studies differ in respect to study designs,
assessment tools, and the size of samples, there is also a degree
of concordance between the neuropsychiatric syndromes found
(Table 1). Thus, delusions and hallucinations have been con-
sistently grouped in a “psychosis” sub-syndrome in all factor
analytical studies using the NPI. A distinct “mood” or “affec-
tive” cluster (depression and anxiety) has been reported by some
studies (Aalten et al., 2007; Zuidema et al., 2007; Dechamps
et al., 2008; Savva et al., 2009; Kang et al., 2010; Spalletta et al.,
2010), while these symptoms have been included in different
sub-syndromes by other authors (e.g., psychosis, agitation; Fuh
et al., 2001; Mirakhur et al., 2004). A less reliable factor char-
acterized by high levels of agitation, aggression, and aberrant
motor behavior has emerged in several studies under various
names (e.g., agitation, hyperactivity, frontal) (Frisoni et al., 1999;
Aalten et al., 2003) presenting with heterogeneous psychopatho-
logical structure and suggesting that psychomotor features co-
occur with psychotic and/or affective symptoms. There is evi-
dence that“psychosis,” “affective,” and “agitation/aggression” factors
remain stable across a 31-month period (Selbæk and Engedal,
2012).
The debate about the deﬁnition of the several psychiatric
and behavioral symptoms in dementia continues as a number
of symptoms (apathy, sleep, and eating disturbances) have not
been grouped consistently across studies. Particularly, the relation
between apathy (highly prevalent in dementia) and the “mood”
sub-syndrome remains unclear. Studies conducted on outpatients
(Aalten et al., 2008; Spalletta et al., 2010) and in nursing-homes
(Zuidema et al., 2007; Dechamps et al., 2008; Selbæk and Engedal,
2012) support that apathy and depression are distinct phenomena
and belong to different neuropsychiatric syndromes. However,
other studies group both symptoms in the same factor (Frisoni
et al., 1999; Aalten et al., 2003; Hollingworth et al., 2006).
These discrepancies may result from the fact that individ-
ual symptoms evolve differently over the course of dementia.
For example, as shown by a large cross-sectional study involv-
ing 3404 subjects, while apathy increases linearly with cognitive
decline, the relations between BPSD and level of cognitive impair-
ment are non-linear with higher prevalence rates observed in the
middle stages of dementia (Lövheim et al., 2008). Several other
cross-sectional studies in both community and institutionalized
populations reported that greater cognitive impairment or demen-
tia severity is associated with higher rates of some BPSD (Table 2).
Yet, other studies were in disagreement with these ﬁndings and a
systematic review found a lack of association between the severity
of dementia and the prevalence of depressive symptoms or diag-
nosed depression (Verkaik et al., 2007). Psychotic (Scarmeas et al.,
2005; Emanuel et al., 2011) and depressive symptoms (Chan et al.,
2011) were reported to predict a faster cognitive deterioration.
There is limited information about the natural history and
course of neuropsychiatric symptoms in MCI. In this context, Ryu
et al. (2011) have concluded that neuropsychiatric symptoms in
MCI usually persist, with a signiﬁcant percentage of patients hav-
ing at least one persistent symptom. These symptoms were more
severe at baseline (Ryu et al., 2011). On the other hand, the pres-
ence of speciﬁc symptoms can aggravate cognitive decline; patients
who present with both amnestic-MCI and apathy, but not those
with depression, had an almost seven-fold risk of AD progres-
sion compared to amnestic-MCI patients without apathy, after
adjustment of variables (Palmer et al., 2010).
Longitudinal studies provided further insight into the evolu-
tion of BPDS during the course of the disease (Table 3). In the
Maastricht Study of Behavior in Dementia (MAASBED) patients
with mild dementia at baseline showed more neuropsychiatric
symptoms, whereas patients with severe dementia showed fewer
neuropsychiatric symptoms throughout 2 years (Aalten et al.,
2005b). Overall, BPSD tend to be present chronically and most
patients with baseline symptoms continue to show at least one
symptom at subsequent assessments. In the population-based
Cache County Study, 67% of dementia subjects with clinically
signiﬁcant symptomspresented at least one symptomboth at base-
line and at 18 months follow-up assessment, with delusions and
depression being the most persistent (Steinberg et al., 2004). In the
MAASBED study 65% of outpatients who had a clinically relevant
NPI total score at baseline continued to experience problems dur-
ing the 2-year study period, with the most persistent symptoms
being apathy and aberrant motor behavior (Aalten et al., 2005a).
Persistence rates over 16 months were highest for delusions, agi-
tation, depression, disinhibition, irritability, and aberrant motor
behavior in a study conducted in nursing homes (Bergh et al.,
2011). Repeated assessments have clariﬁed that individual symp-
toms have an intermittent course, with elevated resolution and
incidence rates throughout the time. Thus, one-third of patients
with delusions, hallucinations, disinhibition, and agitation were
symptom-free in the following 4 months (Bergh et al., 2011).
Although it appears that BPSD have a heterogeneous pattern dur-
ing the course of dementia, it has been proposed, especially in
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Table 1 | Neuropsychiatric sub-syndromes reported in patients with dementia.
Reference Sample/methods Clusters
Devanand et al. (1992) 106 AD patients (outpatient
clinic) BSSD
Disinhibition
Apathy-indifference
Dependency motor agitation
Self-destructive behaviors
Hope et al. (1997) 97 AD or VaD patients
(community)
PBE, PCA
Overactivity : walking more, aimless walking, trailing or checking
Aggressive behavior : aggressive resistance, physical aggression, verbal aggression and hos-
tility
Psychosis: hallucinations, persecutory ideas, anxiety
Harwood et al. (1998) 151 AD patients (outpatient
clinic)
BEHAVE-AD, PCA
Agitation/anxiety : agitation, anxiety of upcoming events, other anxiety
Psychosis: delusions of theft, suspiciousness/paranoia, visual hallucinations
Aggression: verbal aggression, physical treats/violence, fear of being left alone, other delu-
sions
Depression: tearfulness, depressed mood
Activity disturbance: wandering, delusion one’s house is not one’s home
Frisoni et al. (1999) 162 AD patients (hospital)
NPI, PCA
Mood syndrome
Psychosis syndrome
Frontal syndrome
Fuh et al. (2001) 320 AD+212 VaD patients
(outpatient clinic)
NPI, FA
Mood and psychosis
Psychomotor regulation
Social engagement
Lyketsos et al. (2001) 198 AD patients (community)
NPI, LCA
Minimally symptomatic
Affective disturbance (depression, irritability, anxiety euphoria)
Psychotic disturbance (delusions, hallucinations)
Aalten et al. (2003) 199 dementia patients
(outpatient clinic)
NPI, PCA
Hyperactivity : agitation, euphoria, irritability, disinhibition, aberrant motor behavior
Mood/apathy : depression, apathy, sleep, appetite
Psychosis: delusions, hallucinations, anxiety
Mirakhur et al. (2004) 435 AD patients (outpatient
clinic)
NPI, PCA
Affect : depression/dysphoria; anxiety; irritability; agitation/aggression
Physical behavior : apathy; aberrant motor behavior; sleep disturbance; appetite/eating dis-
turbance
Psychosis: delusions; hallucinations
Hypomania: disinhibition; elation/euphoria
Schreinzer et al. (2005) 133 dementia patients
(chronic care hospital)
BEHAVE-AD, PCA
Agitation
Affective disturbance
Altered circadian rhythms
Matsui et al. (2006) 140 AD patients (outpatient
clinic)
NPI, FA
Psychosis: delusions, hallucinations, anxiety, agitation, disinhibition, irritability, aberrant
motor activity
Mood : apathy, depression/euphoria
Euphoria: euphoria
Hollingworth et al. (2006) 1120 AD patients
(community+nursing homes)
NPI, PCA
Behavioral dyscontrol: euphoria, disinhibition, aberrant motor behavior, sleep, appetite
Psychosis: delusions, hallucinations
Mood: depression, anxiety, apathy
Agitation: irritability, aggression
Aalten et al. (2007)
Aalten et al. (2008)
2354/2808 AD patients
(outpatient clinic)
NPI, PCA
Hyperactivity : agitation; euphoria; disinhibition; irritability; aberrant motor behavior Psy-
chosis: delusions; hallucinations; night time behavior disturbance
Affective symptoms: depression; anxiety
Apathy : apathy; appetite/eating abnormalities
(Continued)
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Table 1 | Continued
Reference Sample/methods Clusters
Zuidema et al. (2007) 1437 dementia patients
(nursing homes)
NPI, FA
GDS 4/5:
Factor 1: agitation, disinhibition, irritability, delusions
Factor 2: depression, anxiety, delusions, hallucinations, aberrant motor behavior, night time
behavior
Factor 3: apathy, eating disorders
Factor 4: euphoria
GDS 6
Factor 1: agitation, disinhibition, irritability, euphoria
Factor 2: depression, anxiety
Factor 3: delusions, hallucinations
Factor 4: aberrant motor behavior, night-time behavior
Factor 5 : apathy, eating disorders
GDS 7:
Factor 1: agitation, irritability
Factor 2: delusions, hallucinations, disinhibition
Factor 3: depression, anxiety
Factor 4: apathy, aberrant motor behavior
Factor 5 : night-time behavior, eating disorders
Dechamps et al. (2008) 109 dementia patients
(nursing homes)
NPI, PCA
Hyperactivity : agitation, euphoria, disinhibition and irritability
Affective: depression, anxiety, and eating change
Psychosis: delusions, apathy and aberrant motor behavior
Hallucinations: hallucination and sleeping disturbances
Savva et al. (2009) 587 AD patients (community)
GMS, FA
Factor 1: psychosis, apathy and wandering
Factor 2: anxiety and depression
Factor 3: irritability, persecution, agitation
Factor 4: elated mood, sleep disorder, hallucinations, agitation and wandering
Kang et al. (2010) 778 AD patients (hospital)
NPI, FA (exploratory and
conﬁrmatory)
Hyperactivity : agitation/aggression; disinhibition; irritability
Affect : depression; anxiety
Psychosis: delusions; hallucinations
Apathy/vegetative symptoms: apathy; sleep; appetite
Prado-Jean et al. (2010) 319 dementia patients
(nursing homes)
NPI, PCA
Factor 1: disinhibition, irritability, agitation, anxiety
Factor 2: sleep disorder, aberrant motor behavior, apathy
Factor 3: Euphoria, hallucinations, delusions
Factor 4: Appetite and eating
Garre-Olmo et al. (2010b) 491 AD patients (outpatient
clinic)
NPI, FA (exploratory and
conﬁrmatory)
Psychotic: hallucinations, delusions
Affective: depression, anxiety, irritability, agitation
Behavior : euphoria, disinhibition, apathy, aberrant motor behavior
Spalletta et al. (2010) 1015 AD patients (outpatient
clinic)
NPI, PCA
Psychomotor: agitation, irritability, aberrant motor behavior.
Psychosis: delusions, hallucinations
Affective: anxiety, depression
Maniac: euphoria, disinhibition
Apathetic: apathy
Selbæk and Engedal (2012) 895 dementia patients
(nursing homes)
NPI, PCA
Agitation: agitation, euphoria, disinhibition, irritability, aberrant motor behavior, night-time
behavior
Psychosis/affective: delusions, hallucinations, depression, anxiety
Apathy/appetite: apathy, appetite
AD, Alzheimer disease; BSSD, behavioral syndromes scale for dementia; GMS, geriatric mental state; LCA, latent class analysis; NPI, neuropsychiatric inventory;
NPI-NH, neuropsychiatric inventory-nursing home version; PBE, present behavioral examination; PCA, principal component analysis; VaD, vascular dementia.
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Table 2 | BPSD and dementia severity: cross-sectional studies.
Reference Sample Findings
Aalten et al. (2008) 2808 AD patients (outpatient
clinic)
Psychosis and hyperactivity co-occurred more often in more severe stages
of dementia.
Cheng et al. (2009) 138 (outpatient clinic) +173
(long-term care) AD patients
Severity of delusion/paranoid ideation, hallucination, activity disturbances,
aggressiveness, diurnal rhythm disturbance and behavioral problems
signiﬁcantly associated with severity of dementia.
Craig et al. (2005) 435 AD patients (hospital) Depression/dysphoria and apathy /indifference more frequent in less severe
dementia; hallucinations, elation/euphoria, and aberrant motor behavior
more frequent in severe dementia. Apathy was the most persistent
symptom; psychotic symptoms, delusions, and hallucinations exhibited the
most rapid disappearance over time.
Di Iulio et al. (2010) 119 AD+68
multidomain-MCI+58
amnestic-MCI+107 controls
Apathy more prevalent with increasing severity of cognitive syndromes
(amnestic-MCI to multidomain-MCI, to AD). Depression prevalence
increased from amnestic-MCI to multidomain-MCI, but not with dementia.
No association with night-time disturbances.
Fernández Martínez et al. (2008a) 37 AD+28 VaD patients
(hospital, outpatient clinic)
Behavioral changes without correlation with severity of dementia in AD.
Severity of delusions, hallucinations, aggression, irritability, aberrant motor
behavior, night-time behavior and appetite changes correlated to cognitive
decline in VaD.
Fernández Martínez et al. (2008b) 81 AD+14 VaD+10
PLBD+3FTD (community)
Prevalence of neuropsychiatric symptoms increased with dementia
severity, but was not statistically signiﬁcant.
Fernandez-Martinez et al. (2010) 344 AD+91 MCI+50
controls (hospital, outpatient
clinic)
All behavioral disorders increased with cognitive impairment, except for
sleep and appetite disorders.
Fuh et al. (2005) 320 AD+212 VaD patients
(hospital, outpatient clinic)
Delusions, hallucinations, and aberrant motor activities more common in
later stages in both AD and subcortical VaD.
García-Alberca et al. (2010) 125 AD patients (outpatient
clinic)
No predictive value for MMSE in BPSD.
Geda et al. (2004) 87 AD+54 MCI+514
controls
Total NPI scores signiﬁcantly different among the 3 groups.
Lopez et al. (2003) 1155 AD patients Psychiatric symptoms, except major depression, more frequent in more
severe stages of the dementia.
Lövheim et al. (2008) 3040 residents in geriatric
care centers
Higher prevalence rates of BPSD in the middle stages of dementia.
Passiveness increased linearly with the severity of cognitive impairment.
Lyketsos et al. (2000) 329 dementia patients
(community)
Severity of dementia associated with increased prevalence of
agitation/aggression (13% in mild dementia, 24% in moderate dementia,
and 29% in severe dementia) and aberrant motor behavior (9% in mild,
17% in moderate, and 19% in severe dementia).
Matsui et al. (2006) 140 AD patients (outpatient
clinic)
Psychosis and agitated behaviors co-occurred with dementia progression.
Spalletta et al. (2010) 1015 AD patients (outpatient
clinic)
Poor association between cognitive deﬁcits and severity of BPSD
symptoms.
Thompson et al. (2010) 377 AD+74 VaD patients
(outpatient clinic)
Association between severity of BPSD and severity of dementia
(Continued)
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Table 2 | Continued
Reference Sample Findings
Youn et al. (2011) 216 AD patients (hospital,
outpatient clinic)
Neuropsychiatric symptoms more frequent in moderate-to-severe stages
of AD, except loss of enjoyment and social withdrawal (more frequent in
mild stages). Frequencies of all neuropsychiatric syndromes signiﬁcantly
different in relation to the severity of disease, except for vegetative
symptom. Inertia showed the highest frequency in mild stages.
Zuidema et al. (2010) 1289 dementia patients
(nursing homes)
Dementia severity predicted physically aggressive behavior and apathy,
with higher prevalence in more severe stages of dementia.
NPI, neuropsychiatric inventory; BPSD, behavior and psychological symptoms of dementia; MCI, mild cognitive impairment; AD, Alzheimer disease; VaD, vascular
dementia; RAVLT, Rey auditory verbal learning test; TMT, trail-making test; MMSE, mini mental state examination; PLBD, Parkinson–Lewy body dementia.
AD, that distinct groups of patients can be identiﬁed based on
progressive changes in the frequency and severity of their BPSD
(Garre-Olmo et al., 2010c).
In conclusion, instead of being independent phenomena,BPSD
occur in a psychopathological pattern partially resembling pri-
mary psychiatric disorders, supporting a syndrome approach to
their study and management. However, the psychopathological
proﬁle of each sub-syndrome is highly variable across patients
(Savva et al., 2009). Also, the co-occurrence of sub-syndromes
is common reﬂecting the complex and multi-level interaction
between each BPSD (Dechamps et al., 2008) and supporting a
personalized approach to each patient.
ALZHEIMER’S DISEASE VS. OTHER DEMENTIA TYPES
Although the manifestations of BPSD may be inﬂuenced by a vari-
ety of factors, they are primarily the result of the ongoing patho-
physiological brain changes. It would be reasonable to assume
that, as with the clinical and neuropsychological features, differ-
ent proﬁles of neuropsychiatric symptoms could emerge in each
sub-type of dementia, even at early stages. Thus, a higher preva-
lence of hallucinations and sleep disorders has been reported in
non-amnestic-MCI, more likely to progress to non-AD dementia,
in comparison to amnestic-MCI (Rozzini et al., 2008). How-
ever, studies comparing the proﬁle of BPSD in AD and non-
Alzheimer dementia have not yielded entirely uniform results
(Tables 4 and 5).
ALZHEIMER DISEASE VS. VASCULAR DEMENTIA
The most consistent ﬁnding from the studies comparing vascu-
lar dementia (VaD) with AD is a higher prevalence and severity
of depression and anxiety, similar rates of psychotic symptoms,
and less severe aberrant motor behavior among subjects with
VaD, although a substantial overlap can exist between the two
dementia syndromes (Table 4). Similarly, the type of underly-
ing vascular disease seems to determine a different clinical proﬁle
in VaD as apathy, aberrant motor behavior, and hallucinations
have been associated with small-vessel VaD, whereas euphoria
and agitation/aggression were more severe among patients with
large-vessel VaD (Staekenborg et al., 2010).
ALZHEIMER DISEASE VS. DEMENTIA WITH LEWY BODIES
Studies comparing the clinical proﬁle of autopsy-conﬁrmed cases
of DLB and AD have consistently found a higher prevalence of
delusions (misidentiﬁcation, theft) and hallucinations (usually
visual) in DLB patients independently of gender, ethnicity, and
degree of cognitive impairment (Rockwell et al., 2000). These
symptoms occur in up to 80 and 60% of patients respectively and
tend to be more persistent over the course of the disease compared
with AD patients (Ballard et al., 2001; Chiu et al., 2006; Stavitsky
et al., 2006).
ALZHEIMER DISEASE VS. FRONTO-TEMPORAL LOBAR DEGENERATION
Fronto-temporal lobar degeneration (FTLD) is the prototype of a
neurodegenerative disorderwhere changes in behavior, rather than
in cognitive function, are the presenting feature and dominate the
clinical picture throughout the disease course. The clinical spec-
trum of FTLD encompasses three distinct syndromes. The most
common fronto-temporal dementia (also known as behavioral
variant of fronto-temporal dementia) presents with a dramatic
change in personal and social behavior. Early changes in language
function are observed in semantic dementia and primary progres-
sive non-ﬂuent aphasia (Neary et al., 2005). Stereotypic behavior,
appetite changes, and loss of social awareness are characteristic
of FTLD with complex ritualized behaviors occurring more fre-
quently in patients with fronto-temporal and semantic dementia
than inAD (Bozeat et al., 2000; Ikeda et al., 2002). In contrast, sim-
pler verbal stereotypes/perseveration or stimulus bound behavior,
such as echolalia, seem to be equally common across the three
groups (Nyatsanza et al., 2003). According to Bathgate et al. (2001)
features that best discriminate FTLD from other dementias con-
sist in loss of basic emotions, food cramming, pacing a ﬁxed route,
preserved capacity of locating objects, and impaired insight. Some
behavioral features, such as lack of pain awareness, although not
so common, provide diagnostic speciﬁcity as they are only rarely
seen in other sub-types of dementia (Bathgate et al., 2001). Using
the BEHAVE-AD scale, Chiu et al. (2006) found that AD out-
patients presented with an increased incidence of anxiety and
phobias (61.2%) whereas subjects with fronto-temporal dementia
had higher levels of activity disturbances (92.3%).
OTHER FACTORS ASSOCIATED WITH BPSD
Besides the inﬂuence of dementia stage and subtype on the
emergence of BPSD, other factors such as demographic variables
and the use of medication have not been extensively explored.
A number of associations, albeit not consistently replicated,
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Table 3 | BPSD evolution: longitudinal studies.
Reference Follow-up Findings
Aalten et al. (2005a) 2 years (each 6
months)
No signiﬁcant changes over time in the three sub-syndromes or in the NPI total score.
Depression became less common, persistent and severe with disease progression. Apathy
increased from the second visit (after six months), and persisted during the more advanced
stages of dementia. Psychosis (delusions) was most common in the moderate stages, showing
low persistence over time.
Aalten et al. (2005b) Mild dementia at baseline predicted increasing prevalence of NPS with time, whereas the
reverse was observed with severe dementia. Presence of NPI symptoms at baseline predicted
the subsequent development of symptoms (especially mood/apathy). Hyperactivity predicted
the development of psychosis but not vice-versa.
Bergh et al. (2011) 16 months (each
4 months)
Highest cumulative incidence for irritability (42.6%), disinhibition (37.8%) and depression
(31.5%). High persistence for Delusions, agitation, depression, disinhibition, irritability and
aberrant motor behavior. No signiﬁcant change in the severity of the NPS during the follow-up
period.
Garre-Olmo et al. (2010c) 24-months Increase of psychotic and behavioral symptoms (18–26% and 63–72%, respectively). Affective
symptoms remained stable over the follow-up.
Savva et al. (2009) 2 years Presence of apathy, elated mood or confabulation at follow-up was not signiﬁcantly linked to
their presence at baseline. Conversely, anxiety, depression, and wandering behavior at baseline
were strong indicators for their presence at follow-up. Anxiety, depression, and elation did not
tend to persist. Symptoms of psychosis were more persistent.
Selbaek et al. (2008) 12-month Symptoms were chronically present, although individual symptoms often showed an intermittent
course with higher resolution for depression (58%), delusions (56%), and agitation/aggression
(47%).
Selbæk and Engedal (2012) 31 months The most stable co-occurring symptoms in one and the same factor were depression and
anxiety (affective), agitation, irritability, and disinhibition (agitation), delusions and hallucinations
(psychosis), and apathy and appetite disorder.
Serra et al. (2010b) 12 months Frequency and severity of dysphoria/depression, apathy, agitation/aggression, and anxiety
remained substantially the same at follow-up. Delusions and irritability/lability increased
signiﬁcantly.
Steinberg et al. (2004) 18 months Delusions and depression were the most persistent, while disinhibition was the least.
Tschanz et al. (2011) 3.8 years
Drop-out: 29%
Increasing occurrence, rate, and overall severity of NPS over time. Rate of change in NPS was
weakly correlated with rate of change in cognition or function.
Wancata et al. (2003) 6 months
Drop-out: 26.9%
While, at T1, 33.7% suffered from any marked or severe non-cognitive symptoms, 11.6%
remitted from these symptoms within 6 months.
Weamer et al. (2009) 2 years Greater global cognitive impairment was present at base line in subjects who developed
psychosis at follow-up.
Wetzels et al. (2010) 2 years Agitation, irritability, and aberrant motor behavior were the most prevalent over the 2 years.
Affective symptoms decreased, apathy tended to increase. Agitation and aberrant motor
behavior were the most persistent symptoms.
have been described between neuropsychiatric symptoms, and
patient-related or environmental factors.
PATIENT-RELATED FACTORS
Demographic factors
Aggressiveness or aberrant motor behavior has been more fre-
quently reported inmenwith dementia whereas female gender has
been associated with depressive/anxious symptoms and verbally
agitated help-seeking behavior (Lövheim et al., 2009; Zuidema
et al., 2010; Karttunen et al., 2011). In one study, female elderly
with VaD had more neuropsychiatric symptoms than male elderly
(Hsieh et al., 2009). In other studies, age and gender did not
inﬂuence the likelihood of BPSD manifestation in AD or VaD
(Savva et al., 2009; Di Iulio et al., 2010; Staekenborg et al., 2010).
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Table 4 | BPSD:Alzheimer’s disease vs. vascular dementia.
Reference Sample Findings
Aharon-Peretz et al. (2000) 30 AD+30 VaD Aggression, depression, anxiety and apathy signiﬁcantly more severe in VaD-WSI than in AD.
Ballard et al. (2000a) 92 AD+92 VaD Depression and anxiety more common in VaD than in AD. Psychotic symptoms similarly
common in VaD and in AD.
Chiu et al. (2006) 85 AD+32 VaD VaD with higher incidence of paranoid and delusional ideation and affective disturbance.
Fernández Martínez et al. (2008a) 37 AD+28 VaD Sleep disturbances and appetite changes more prevalent in AD than in VaD. Aberrant motor
activity more common in subcortical VaD.
Fernández Martínez et al. (2008b) 81 AD+14 VaD Similar prevalence of BPSD in AD and VaD.
Fuh et al. (2005) 320 AD+212 VaD Similar prevalence in AD, cortical VaD, sub-cortical VaD, and mixed VaD. More severe sleep
disturbance in cortical VaD than in AD.
Hsieh et al. (2009) 77 AD+77 VaD Higher prevalence of night-time behavior (sleep disturbance) in AD; higher prevalence of
depression in VaD. Similar prevalence of delusions, hallucinations, and agitation in AD and VaD
Ikeda et al. (2004) 21 AD+28 VaD Delusions and aberrant motor behavior more likely in AD.
Kim et al. (2003) 99 AD+36 VaD Depression and anxiety signiﬁcantly more severe in VaD than in AD.
Lyketsos et al. (2000) 214 AD+62 VaD Delusions more likely in AD and depression more frequent in VaD.
Lyketsos et al. (2002) 258 AD+104 non-AD Similar prevalence in AD and non-AD dementia, except for more frequent aberrant motor
behavior in AD.
Srikanth et al. (2005) 44 AD+31 VaD Similar symptom proﬁle in AD and in VaD.
Thompson et al. (2010) 377 AD+74 VaD No signiﬁcant difference in AD and VaD patients on the BPCL or on the RMBPCL.
AD, Alzheimer disease; VaD, vascular dementia; VaD-WSI, ischemic white matter subcortical changes and lacunar infarctions; BPCL, behavior problems check list;
RMBPCL, revised memory and behavior problems check list.
Table 5 | BPSD:Alzheimer’s disease vs. fronto-temporal lobar degeneration.
Reference Sample Findings
Bathgate et al. (2001) 30 FTD+75 AD+34 VaD Loss of basic emotions, food cramming, pacing a ﬁxed route, an absence of
difﬁculty in locating objects, and an absence of insightfulness differentiated FTD
from other dementias.
Bozeat et al. (2000) 13 FTD+20 SD+37 AD Stereotypic and eating behavior and loss of social awareness more common in the
FTD group. Mental rigidity and depression more frequent in SD than in FTD. Patients
with FTD more disinhibited.
Chiu et al. (2006) 17 FTD+85 AD+32 VaD Higher incidence of activity disturbances in FTD.
Fernández Martínez et al. (2008b) 3 FTD+81 AD+14 VaD Higher aberrant motor activity prevalence in FTD.
Ikeda et al. (2002) 23 FTD+25 SD+43 AD Changes in eating behaviors more common in both FTLD groups compared with AD.
Levy et al. (1996) 22 FTD+30 AD Higher scores for disinhibition, apathy, aberrant motor behavior, and euphoria in
patients with FTD compared with AD.
Nyatsanza et al. (2003) 18 FTD+13 SD+28 AD Complex ritualized behaviors were signiﬁcantly more frequent in patients with fvFTD
and semantic dementia than in AD.
Srikanth et al. (2005) 23 FTLD+44 AD+31 VaD Disinhibition, aberrant motor behavior, and appetite/eating disturbances could
reliably differentiate AD and VaD from FTLD.
AD, Alzheimer disease; FTLD, fronto-temporal lobar degeneration; FTD, fronto-temporal dementia; SD, semantic dementia.
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Considering that most studies included white population from
northern European descent it’s difﬁcult to make assumptions
about whether different symptom proﬁle may arise according to
ethnicity as reported by a few studies (Chen et al., 2000; Chow
et al., 2002). In the study by Kim et al. (2003), age of onset and
duration of dementia did not show any signiﬁcant correlationwith
BPSD in patients with AD or VaD. Toyota et al. (2007) found con-
versely that early onset AD patients showed fewer BPSD than their
late onset counterparts, particularly delusions, hallucinations, agi-
tation, disinhibition, and aberrant motor behavior although this
was not conﬁrmed by a recent study (Garre-Olmo et al., 2010a).
Psychotropic medication
Aggressiveness and psychotic symptoms in outpatients with
dementia have been found to increase the likelihood of receiv-
ing psychotropic medications by at least two-fold and this was
coupled with a higher caregiver burden (Chiu et al., 2006). How-
ever, conclusions regarding the effects of medication on the natural
course of BPSD are unclear as most studies don’t have available
data concerning the usual treatment of patients or don’t include
sub-analysis regarding this variable. Aalten et al. (2008) reported
that the use of cholinesterase inhibitors (ChEI) inﬂuenced the
structure of the apathy factor. Although this ﬁnding could derive
from a therapeutic effect the available evidence suggests a modest
impact of these drugs onneuropsychiatric symptoms (Rodda et al.,
2009).The same holds true for antipsychotics which have been
found to have little effect on the sub-syndrome factor structure of
BPSD (Aalten et al., 2008).
Psychopathological symptoms
Depression affects up to 43% of patients with dementia and
it predicts an increased number of neuropsychiatric symptoms,
particularly agitation, anxiety, and irritability (Prado-Jean et al.,
2010). Lack of insight occurs in the majority of AD patients even
in early stages and appears to be an important predictive factor for
the occurrence of increased levels of neuropsychiatric symptoms
including apathy, agitation, irritability, psychosis, or behavioral
symptoms in general (Vogel et al., 2010).
Neuropsychological deﬁcits
The presence of alterations in speciﬁc cognitive domains may have
a predictive value for the occurrence of BPSD. Psychotic symptoms
in AD patients have been found to correlate with impairments in
verbal ﬂuency (Tsai et al., 2010) and in verbal learning tasks (Starr
and Lonie, 2007). Premorbid IQ has been proposed to mediate the
relationship between BPSDs and cognition inAD as it signiﬁcantly
correlated with mood, frontal, and psychotic factors (Starr and
Lonie, 2007). In a cross-sectional study, impairments in memory
(episodic and semantic), executive function, and verbal ﬂuency
all correlated with the severity of neuropsychiatric symptoms
(García-Alberca et al., 2010). The presence of speciﬁc neurocogni-
tive deﬁcits, such as executive dysfunction, was reported to predict
greater BPSD symptom severity in patients with MCI, particularly
of depression and anxiety (Rosenberg et al., 2011).
ENVIRONMENTAL FACTORS
Presence of neuropsychiatric symptoms may arise from the char-
acteristics of psychosocial/physical environment, such as crowded
housing conditions leading to sensory overstimulation (for which
patientswith dementia aremore susceptible), attitudes of care staff
toward challenging behaviors and/or the size of the units in which
patients reside throughout the day (Zuidema et al., 2010). Simi-
larly, patients being restrained, or subjected to multiple moves and
procedures, may also contribute to a range of BPSD symptoms,
especially wandering and aggression (Kunik et al., 2010).
PATHOPHYSIOLOGY AND NEUROBIOLOGY OF BPSD
The behavioral or psychological disturbances occurring in demen-
tia can be understood as ineffective attempts of the patient to cope
with environmental or physiological stress factors. Indeed, BPSD
are also common in non-demented older adults with rates of 5.6%
for anxiety, 4.5% for irritability and 2.8% for agitation/aggression
(Lyketsos et al., 2000) while psychotic symptoms are present in up
to 10.5% of Swedish 85 years-old people (Ostling et al., 2009). It is
important, therefore, to trace back these symptoms to premorbid
psychosocial functioning which is determined by constitutional
factors (e.g., personality traits, cognitive styles, and emotional
reactivity), past experiences and level of education. Abnormalities
in the intensity, magnitude, duration, timing, and modiﬁability of
internal conditions and/or observable behaviors are expected to
emerge beyond the limits of normal variability as the ongoing neu-
ropathological changes of dementia undermine the individual’s
usual psychological capacities to adequately respond to every-
day demands. Deﬁning these neuroanatomical and neurochemical
correlates of BPSD has been an area of active research with a hope
that clariﬁcation of the underlying neurobiology will lead to more
effective treatments (Tables 6–8).
PSYCHOSIS
Not many studies have examined the neuropathological correlates
of psychosis in AD. Two studies found an association of psychosis
with increased severity of beta-amyloid senile plaques (SP) in the
presubiculum (Zubenko et al., 1991) and across cortical regions
(Mukaetova-Ladinska et al., 1995). Förstl et al. (1994) reported
changes in neuronal counts in the CA1 hippocampus and parahip-
pocampal gyrus, while Zubenko et al. (1991) described increased
density of neuroﬁbrillary tangles (NFT) in the middle frontal cor-
tex. Furthermore, Farber et al. (2000) reported that AD patients
with psychosis had a 2.3-fold greater density of neocortical NFTs
than AD subjects devoid of psychotic symptomatology. However,
no similar relation was observed in non-neocortical areas or with
SP burden. On the other hand, no signiﬁcant differences were
found between AD patients with (n = 24) and without (n = 24)
psychosis in respect to SP and NFT densities in the study by Sweet
et al. (2000). Consistentlywith the neocortical role underlying psy-
chotic symptomatology,AD subjects with psychosis demonstrated
signiﬁcant elevations of glycerophosphoethanolamine and signif-
icant reductions of N -acetyl-l-aspartate in temporal, frontal, and
parietal cortices (Sweet et al., 2002).
Neuroimaging studies have similarly conﬁrmed severe abnor-
malities in grey matter volume, cerebral blood ﬂow, and metab-
olism in the above cortical regions of AD subjects with psychotic
symptoms (reviewed in Casanova et al., 2011). Anatomically,
these changes partially coincide with cholinergic and dopamin-
ergic pathways supporting, together with neurochemical and
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Table 6 | BPSD and structural changes in neuroimaging exams.
Symptoms Findings References Sample
Computerized tomography
Delusional misidentiﬁcation Right frontal and temporal atrophy Förstl et al. (1994) 56 AD patients
Magnetic resonance imaging
Depression Decreased gray matter volume in right hippocampus and amygdala Egger et al. (2008) 14 AD patients
Apathy Anterior cingulated gyrus, orbitofrontal, and frontosubcortical areas
atrophy
Tunnard et al. (2011) 111 AD patients
Bruen et al. (2008) 31 mild AD patients
Massimo et al. (2009) 40 FTLD patients
Delusions Decreased GM volume in frontal, temporal, and limbic regions Bruen et al. (2008) 31 mild AD patients
Massimo et al. (2009) 40 FTLD patients
Visual hallucinations Lesions on visual cortex and association areas detected in MRI Holroyd et al. (2000) 14 AD patients
Agitation Anterior cingulated cortex and left insula atrophy Bruen et al. (2008) 31 mild AD patients
Aggressive behavior Amygdala atrophy Poulin et al. (2011) 264 AD patients
Disinhibition Cingulate frontal cortex atrophy and medial orbital frontal cortex
atrophy
Serra et al. (2010a) 54 AD patients
Massimo et al. (2009) 40 FTLD patients
Anxiety, sleep disorders,
and aberrant motor behavior
Increased WMH volume Berlow et al. (2010) 37 AD patients
AD, Alzheimer disease; FTLD, fronto-temporal lobar degeneration; GM, gray matter; MRI, magnetic resonance imaging; WMH, white matter hyperintensities.
Table 7 | BPSD and functional changes in neuroimaging exams (PET and SPECT studies).
Symptoms Findings References Sample
Depression Hypoperfusion and hypometabolism in some areas of
temporal, frontal, and parietal lobes
Hirono et al. (1998) 53 AD patients
Staffen et al. (2009) 149 MCI+131 DA+127 DCI patients
Apathy Decreased perfusion and hypometabolism in anterior
cingulated gyrus, orbitofrontal, and frontosubcortical areas
Lanctôt et al. (2007b) 51 AD patients
Benoit et al. (1999) 63 AD patients
Marshall et al. (2007) 41 AD patients
Craig et al. (1996) 31 AD patients
Psychosis Hypometabolism in frontal lobe Sultzer et al. (1995) 21 AD patients
Hallucinations Hypoperfusion in parietal lobe Kotrla et al. (1995) 30 AD patients
Delusions Hypometabolism of prefrontal, anterior cingulate, right
temporal, and parietal cortex
Staff et al. (2000) 45 AD patients
Sultzer et al. (2003) 25 AD patients
Increased metabolism in the inferior temporal gyrus and
decreased metabolism in the occipital lobe
Hirono et al. (1998) 65 AD patients
Agitation Changes in metabolism in frontal and temporal cortices Sultzer et al. (1995) 21 AD patients
Aggressive behavior Hypoperfusion in the temporal cortex (right middle and left
anterior)
Lanctôt et al. (2004) 49 AD patients
Hirono et al. (2000) 10 dementia patients
AD, Alzheimer disease; MCI, mild cognitive impairment; FTLD, fronto-temporal dementia; DCI, depression with cognitive impairment (DCI).
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Table 8 | Associations between BPSD and genes.
References Gene Sample Pathway Clinical correlates
Borroni et al. (2006) COMT 232 AD patients Dopamine Higher risk for “psychosis” (ORs=3.05, 2.38, and 1.80 for
delusions, hallucinations, and sleep disturbance symptoms,
respectively) p<0.05
Lower risk for “frontal” endophenotype (ORs=0.25 and
0.25 for disinhibition and euphoria, respectively). P <0.05
5-HTTLPR Serotonin Lower risk for “psychosis” (ORs=0.32, 0.41, and 0.54 for
disinhibition and euphoria, respectively)
APOE4 No correlation with any endophenotype
Angelucci et al. (2009) 5-HT2A receptor
polymorphism (102T/C)
80 AD patients Serotonin Delusions associated withT allele (p<0.05)
Di Maria et al. (2009) G72 gene (locus DAO) 185 AD patients Glutamate Delusions and hallucination (p<0.05)
Proitsi et al. (2012) SERT STin2 12R 1008 AD patients Serotonin Less “psychosis” (p=0.025) and less apathy (p=0.007)
DAT 10R Dopamine Increased agitation (p=0.003) increased aberrant motor
behavior (p=0.009)
DRD4 2R Increased “moods” levels (p=0.004); increased sleep
abnormalities (p=0.032)
DRD1 G Higher irritability (p=0.01); lower aberrant motor behavior
(p=0.023)
DRD3 Bal I C Lower depression (p=0.007)
COMT, catechol-O-methyl transferase; 5-HTTLPR, serotonin gene-linked polymorphic region; APOE, apolipoprotein E; 5-HT2A, serotonin 2A receptor; DAO, D-amino
acid oxidase; SERT STin2, serotonin transporter gene polymorphism STin2; DAT, dopamine transporter gene; DRD4, dopamine receptor 4; DRD1, dopamine receptor
1; DRD3, dopamine receptor 3 Ball polymorphism.
pharmacological evidence, the role of acetylcholine and dopamine
imbalance in the pathogenesis of AD psychosis (reviewed in Pinto
et al., 2011). Psychosis has also been associated with the relative
preservation of norepinephrine in the substantia nigra and a sig-
niﬁcant serotonin reduction in the presubiculum (Ismail et al.,
2011). A strong hereditability has been reported for psychosis in
AD, suggesting an important role for APOE4 (Ismail et al., 2011).
Other genes have also been associated with higher risk of psychosis
[(COMT,G72 gene (locusDAO); 5-HT2A receptor polymorphism
(102T)]while othersmay be“protective”(5-HTTLPR,SERTSTin2
12R; Table 8). In DLB, visual hallucinations have been linked to
higher Lewy Body density in the temporal cortex and amygdala
(Harding et al., 2002; Tsuang et al., 2009) and with less severe
density of neocortical tangles (Ballard et al., 2004). Cholinergic
deﬁcits have been described for hallucinations and delusions in
both AD (Tsang et al., 2008) and DLB (Ballard et al., 2000b; Teak-
tong et al., 2005), thus providing a rationale for the therapeutic
use of cholinergic drugs to treat these symptoms.
DEPRESSION
Several lines of evidence suggest that depression shares complex
pathophysiological routeswith dementia. It has been hypothesized
that chronic depressionmay accelerate neurodegenerative changes
of AD as a result of the neurotoxic effects of elevated cortisol levels
in the hippocampus (Korczyn and Halperin, 2009). Moreover, the
observation that the late-life depressive disorders are commonly
associated with increased number of white matter hyperdensities
in subcortical areas supported the so-called “vascular hypothesis”
of depression (Alexopoulos, 2005). Reversely, neurodegenerative
and vascular changes may act as a risk factor for depression.
Depressed non-demented patients present with chronic eleva-
tion of inﬂammatory mediators, known to play a central role in
AD pathogenesis, together with altered serotonin metabolism and
reduced neurotrophic activity (Caraci et al., 2010). So, in addition
to being merely an emotional reaction to early memory deﬁcits
depression can be a prodromal symptom of dementia, a risk fac-
tor for neurodegeneration or co-occur with cognitive impairment.
Post-mortem studies in AD subjects found higher burden of neu-
ropathological lesions in thosewith a lifetimehistory of depression
(Rapp et al., 2006) or presentingwith concurrent depression (Rapp
et al., 2008). Functional imaging studies revealed decreased per-
fusion and hypometabolism in the temporal, frontal, and parietal
cortex, as well as in thalamus and lentiform nucleus of depressed
compared to non-depressed AD patients (Hirono et al., 1998;
Staffen et al., 2009). However, in other post-mortem studies in
AD subjects with depressive symptoms were not related to the
level of pathology (Wilson et al., 2003; Sweet et al., 2004).
The only prospective study assessing brain tissue from
dementia-free subjects (n = 153) did not ﬁnd increased AD
or cerebrovascular pathology in those with late-life depression
(Tsopelas et al., 2011), suggesting that depression per se may be
linked to additional,more subtle neuropathological and/or neuro-
biochemical changes, such as those involving the neurotransmitter
systems. Indeed, a disturbed serotoninergic system has been asso-
ciated with depressive symptoms in AD as several areas of the
brain exhibit decreased serotonin concentration,with a signiﬁcant
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reduction in 5-HT1 and 5-HT2 receptors throughout the cerebral
cortex (Lanari et al., 2006). Similarly, loss of noradrenergic cells
in consequence of degeneration of the locus coeruleus is also seen
in individuals with dementia who manifest depressive symptoms
(Lanari et al., 2006). Changes of GABAergic plasma levels observed
in ﬁnal stages of AD have also been associated with depression,
apathy, and aggressive behaviors (Lanctôt et al., 2007a). Associ-
ation between genetic factors and depression are summarized in
Table 8.
APATHY
Post-mortem and in vivo studies suggest that AD is associated
with a dysfunctional dopaminergic system, since reduced levels
of dopamine (DA) and homovanilic acid, as well as altered DA
receptor density, have been described in discrete brain regions
coinciding with the mesocorticolimbic pathway (Mitchell et al.,
2011). On the other hand, neuroimaging studies in AD have been
consistently showing a signiﬁcant association between apathy and
changes in the brain reward system including atrophy (Apostolova
et al., 2007; Bruen et al., 2008; Tunnard et al., 2011), hypoperfu-
sion and hypometabolism (Craig et al., 1996; Benoit et al., 1999;
Lanctôt et al., 2007b; Marshall et al., 2007) in the anterior cingu-
lated gyrus and orbitofrontal areas (Tables 6, 7). It is also possible
that dysfunction in these areas underlies the reported relation
between increased frontal whitematter changes and apathy (Stark-
stein et al., 2009) together with disruption of deep white matter
afferents and efferents to the basal ganglia and/or by decrement of
metabolic activity in frontal subcortical regions. In FTD subjects,
apathy has been associated with atrophy in the anterior cingulated
cortex, right dorso-lateral prefrontal cortex (Massimo et al., 2009),
and adjacent medial frontal cortex (Rosen et al., 2005). This sug-
gests that dysfunction in the frontosubcortical cingulate pathways
is implicated in apathy regardless of the sub-type of dementia.
OTHER SYMPTOMS
Increased burden of NFT in the orbitofrontal cortex has been
linked to agitation (Tekin et al., 2001), while aggressive behav-
iors have been associated with neuronal loss in locus ceruleus
(Matthews et al., 2002). Deterioration of brainstem regions and
in the suprachiasmatic nucleus of the hypothalamus has been
reported in patients with sleep disorders (Yesavage et al., 2003).
MANAGEMENT OF BPSD
Management of BPSD is a key component of a comprehen-
sive approach to the treatment of dementia requiring the judi-
cious combination of pharmacological and non-pharmacological
interventions. Treatment of these symptoms remains problemat-
ical, with an increased risk of psychotropic medication misuse,
and, thus, represents an important challenge for clinicians. Cur-
rent guidelines recommendnon-pharmacological interventions as
ﬁrst-line treatment followed by the least harmful medication for
the shortest time possible (Gauthier et al., 2010; Azermai et al.,
2011).
NON-PHARMACOLOGICAL INTERVENTIONS
Non-pharmacological interventions have been classiﬁed into the
following categories (O’Neil et al., 2011): (i) cognitive/emotion-
oriented interventions (reminiscence therapy, simulated presence
therapy, validation therapy); (ii) sensory stimulation interventions
(acupuncture, aromatherapy, light therapy, massage/touch, music
therapy, Snoezelenmultisensory stimulation, transcutaneous elec-
trical nerve stimulation); (iii) behavior management techniques;
and (iv) other psychosocial interventions such as animal-assisted
therapy and exercise. Unfortunately, despite efforts in investigating
these interventions, consistent evidence about the efﬁcacy of the
various psychosocial therapies is lacking (Kong et al., 2009). Ben-
eﬁts from psycho-educational interventions for caregivers were
documented to be long-lasting, especially when delivered indi-
vidually (Livingston et al., 2005). Special care units have been
developed since the 1980s and are commonly situated in nursing
homes. They include the features of trained stafﬁng, a modi-
ﬁed physical environment, and family involvement (Lai et al.,
2009).
Speciﬁc therapeutic interventions for different symptoms of
BPSD have also been investigated. In relation to agitation and
aggressive behavior, and before opting for any intervention, it
is important to carefully analyze the causes for the disruptive
behavior: such causes may include pain, medical illness, fatigue,
depression, loneliness, understimulation, or overstimulation; and
social and environmental stressors (Iwata et al., 1993; Salzman
et al., 2008). Strategies reported to be useful to reduce agitation
include sensory interventions, particularly music therapy (Choi
et al., 2009), aromatherapy (Ballard et al., 2009), and environmen-
talmodiﬁcation (Weitzel et al., 2011). Regarding depression, recent
studies support the effectiveness of home-based exercise programs
for people with dementia and their caregivers to reduce depressive
symptoms (Prick et al., 2011). Recently animal-assisted activities
were suggested to be associated with a decrease in anxiety and
sadness and an increase in positive emotions and motor activity
(Mossello et al., 2011).
PHARMACOLOGICAL INTERVENTIONS
A variety of medications have been used to treat BPSD including
typical and atypical antipsychotics, antidepressants, anticonvul-
sant mood stabilizers, ChEI, benzodiazepines, and other drugs,
such as memantine. These drugs have variable efﬁcacy and effec-
tiveness in treating BPSD, depending on the target symptom and
class of medication. The pharmacological treatment of BPSD
should consider the presence of additional comorbidities and asso-
ciated medications, which increase signiﬁcantly the risk of both
medical complications and drug interactions. Current guidelines
recommend careful consideration of both beneﬁts and limitations
of each drug class with the use of the least harmful medication for
the shortest time possible (Gauthier et al., 2010).
Antipsychotics
The use of antipsychotics, particularly since the introduction of
atypical antipsychotics, has increased over time (Briesacher et al.,
2005). They have shown efﬁcacy in treating speciﬁc symptoms,
such as aggression, psychosis, and agitation (Ballard et al., 2008;
Gauthier et al., 2010).However the evidence regarding other BPSD
symptoms is not convincing (Ballard et al., 2008). Despite serious
side effects, including extrapyramidal symptoms, sedation, tar-
dive dyskinesia, gait disturbances, falls, anticholinergic side effects,
cerebrovascular events, and increased mortality, antipsychotic are
Frontiers in Neurology | Dementia May 2012 | Volume 3 | Article 73 | 14
Cerejeira et al. Behavioral and psychological symptoms of dementia
still widely used off-label (Azermai et al., 2011). Risperidone, olan-
zapine, and haloperidol appear to be more effective for managing
BPSD (Azermai et al., 2011). A recent study on dementia patients
reported a 1.5-fold increase in mortality associated with the use
of haloperidol, compared to risperidone, olanzapine or quetiap-
ine. The mortality risk with haloperidol was highest during the
ﬁrst 30 days and decreased signiﬁcantly over time (Kales et al.,
2012). The use of an antipsychotic for severe symptoms such as
agitation, aggression, and psychotic symptoms should be time-
limited and a careful individual evaluation is recommended due
to increased risk of stroke and mortality. In the UK, risperidone
is licensed for up to 6 weeks treatment of persistent aggression
in subjects with moderate-to-severe AD, and the recommenda-
tions are to be used as a last resort for aggression, when all other
methods have failed to alleviate the most distressing symptoms
of dementia, and only when it is in the best interests of the per-
son (https://www.alzheimers.org.uk/antipsychotics). It is prudent
to initiate with a low dose and regularly review the prescrip-
tion in function of the patient’s response and presence of adverse
events.
Antidepressants
Antidepressants can be an effective and well-tolerated alternative
to antipsychotics in vulnerable elderly individuals for treatment
of BPSD (Henry et al., 2011). This class of drugs has been used
primarily for depression, with efﬁcacy especially for the selective
serotonin reuptake inhibitors (SSRIs; Gauthier et al., 2010). Some
authors found that citalopramand sertraline could improve symp-
toms of agitation and psychosis in subjects with dementia with
similar efﬁcacy, but better tolerability and safety, than haloperi-
dol and risperidone (Gauthier et al., 2010; Seitz et al., 2011).
Citalopram was effective in treating disinhibition, irritability and
depression and also behaviors speciﬁc to FTD (Herrmann et al.,
2011). However, the evidence so far does not support the use of
these medications for BPSD other than depression (Azermai et al.,
2011).
Cholinergic inhibitors
Current guidelines support the use of ChEI for BPSD although dif-
ferent recommendations exist to each speciﬁc drug (Gauthier et al.,
2010). Donepezil, galantamine, or rivastigmine have all shown a
modest effect on the broad spectrum of neuropsychiatric symp-
toms in AD (Rodda et al., 2009). They should be initiated prior to
the use of other psychotropic agents since ChEIs reduce behavioral
changes and improve or delay cognitive and functional decline
(Gauthier et al., 2010). The behavioral symptoms most likely to
improve with ChEIs treatment appear to be apathy, depression,
and aberrant motor behavior (Cummings, 2004; Holmes et al.,
2004; Feldman et al., 2005).
Memantine
Memantine, an NMDA receptor antagonist, can also have bene-
ﬁcial effects on behavior, as well as on cognition and function;
however there is insufﬁcient evidence to recommend its use (Azer-
mai et al., 2011). Theuse of memantine appears to improve speciﬁc
behaviors, such as agitation and irritability, which differ from
those affected by ChEIs (mood symptoms, apathy, and aberrant
motor behavior). Combination therapy may have advantages in
patients with multiple BPSD (Gauthier et al., 2010). The latest
report on combined memantine and ChEIs (donepezil) treatment
did not show any major advantages on cognitive and behavioral
changes in subjects with moderate-to-severe AD, compared to
those treated with either memantine or donepezil, with only neg-
ligible improvement on the NPI scores in the subjects treated with
the combination of the two antidementia drugs (Howard et al.,
2012).
Anticonvulsants
Anticonvulsant mood stabilizers such as carbamazepine, valproic
acid, gabapentin, lamotrigine, topiramate are widely used in clini-
cal practice. Treatment regimens with anticonvulsant mood stabi-
lizers have shown promising results and seem to be beneﬁcial for
some dementia patients (Konovalov et al., 2008). Anticonvulsants
may allow dose reduction of antipsychotics; however, investiga-
tion regarding beneﬁts, safety, and tolerability of these drugs has
produced mixed results, so they are not recommended for rou-
tine use. In particular sodium valproate has been shown to be
ineffective in the treatment of agitation in AD, and has been asso-
ciated with increased adverse effects, including falls, infection, and
gastrointestinal disorders (Lonergan and Luxenberg, 2009).
Benzodiazepines
Benzodiazepines may be used at short-term for acute agitation or
agitation associated with anxiety (Azermai et al., 2011).
CONCLUSION
Neuropsychiatric symptoms are frequent in dementia and con-
tribute signiﬁcantly for burden caregiver and illness costs. Cor-
rect identiﬁcation and evaluation of these symptoms is a crucial
part of the clinical approach to dementia. Despite the tenta-
tive efforts to group different symptoms into clusters (to facili-
tate clinical/diagnostic investigations), there is not yet an estab-
lished model. The pathogenesis of these symptoms is not well
understood, and the current knowledge supports multifactor-
ial causes. Development and use of new speciﬁc investigation
techniques may be helpful to better understand the underlying
etiological mechanisms of various neuropsychiatric symptoms.
At present, combination of non-pharmacological and appropri-
ate pharmacological strategies represents the best treatment of
BPSD. However, there is no consistent evidence about speciﬁc
strategies for individual symptoms. It is necessary to encourage
application of novel non-pharmacological interventions, which
are safer than pharmacological therapies. Further investigation is
similarly needed to ﬁnd more effective, safe, and well-tolerated
pharmacological therapies. This will help to devise novel, more
symptom targeted, and speciﬁc interventions that will improve
signiﬁcantly the management of BPSD symptoms in subjects with
dementia.
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